By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene ...

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline ...

Lilly inks gene therapy deal with Seamless Therapeutics to develop programmable recombinase treatments targeting genetic hearing loss worldwide.

Both companies may succeed in this industry.

The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of ...

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major ...

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

Eli Lilly expand 340B reporting requirements to include all covered entities submitting claims-level data by Feb. 1, 2026, with some state exemptions.